Personalized FLT3 Mutation-Based Cancer Treatment Platform

A comprehensive platform integrating FLT3 mutation detection, adaptive crenolanib dosing, and treatment outcome prediction to revolutionize cancer treatment.

The original patent disclosed the use of crenolanib for treating FLT3 mutated proliferative disorders, but it has limitations in terms of personalized treatment and adaptive dosing. The new inventive concept addresses these limitations by introducing a system that can detect FLT3 mutations, adjust crenolanib dosing, and predict treatment outcomes, thereby providing a more effective and targeted approach to cancer treatment.

The platform consists of three interconnected modules: a FLT3 mutation detection module, a crenolanib dosing module, and a treatment outcome prediction module. The FLT3 mutation detection module uses advanced genomics techniques to identify specific FLT3 mutations in a patient's biological sample. The crenolanib dosing module uses this information to adaptively adjust the dosing regimen based on the patient's mutation profile and treatment response. The treatment outcome prediction module utilizes machine learning algorithms trained on a dataset of FLT3 mutation profiles and corresponding treatment outcomes to generate a prediction of the patient's likelihood of responding to treatment. The platform can be integrated with existing healthcare infrastructure, enabling clinicians to make data-driven decisions and improve patient outcomes.

The new inventive concept introduces a paradigm shift in cancer treatment by integrating FLT3 mutation detection, adaptive dosing, and treatment outcome prediction in a single platform. This integrated approach enables personalized treatment and improves treatment outcomes, which is not possible with the original patent's method.

Alternative embodiments of the platform could include the use of different genomics techniques, such as CRISPR-Cas9, or the integration of additional biomarkers to further personalize treatment. Variations of the platform could be developed for different types of cancer, such as solid tumors or hematological malignancies.

The personalized FLT3 mutation-based cancer treatment platform has significant commercial potential in the oncology market, with potential applications in precision medicine, companion diagnostics, and targeted therapies. The platform could be marketed to pharmaceutical companies, biotech firms, and healthcare providers, with potential revenue streams from licensing, partnerships, and sales.